Dynavax Technologies (DVAX) 10-Q2 Nov 232023 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2023	Oct. 31, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Trading Symbol	DVAX
Entity Registrant Name	Dynavax Technologies Corporation
Entity Central Index Key	0001029142
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		129,260,850
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity File Number	001-34207
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0728374
Entity Address, Address Line One	2100 Powell Street
Entity Address, Address Line Two	Suite 720
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	848-5100
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 154,511	$ 202,004
Marketable securities available-for-sale	565,905	422,391
Accounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at September 30, 2023 and December 31, 2022, respectively	46,347	145,130
Other receivables	519	2,385
Inventories	49,412	59,446
Prepaid expenses and other current assets	18,972	85,629
Total current assets	835,666	916,985
Property and equipment, net	36,183	37,596
Operating lease right-of-use assets	24,949	25,745
Goodwill	1,981	2,006
Other assets	74,154	3,518
Total assets	972,933	985,850
Current liabilities:
Accounts payable	3,120	3,211
Accrued research and development	3,290	4,775
CEPI accrual (Note 6)	0	107,738
Accrued liabilities	43,462	30,719
Other current liabilities	4,392	3,631
Total current liabilities	54,264	150,074
Convertible Notes, net of debt discount of $3,085 and $3,922 at September 30, 2023 and December 31, 2022, respectively (Note 7)	222,415	221,578
Long-term portion of lease liabilities	30,680	32,801
CEPI accrual long-term	60,337	0
Other long-term liabilities	321	384
Total liabilities	368,017	404,837
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock: $0.001 par value; 5,000 shares authorized at September 30, 2023 and December 31, 2022; zero shares outstanding at September 30, 2023 and December 31, 2022, respectively	0	0
Common stock: $0.001 par value; 278,000 shares authorized at September 30, 2023 and December 31, 2022; 129,195 shares and 127,604 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	129	128
Additional paid-in capital	1,541,549	1,510,518
Accumulated other comprehensive loss	(5,959)	(5,438)
Accumulated deficit	(930,803)	(924,195)
Total stockholders’ equity	604,916	581,013
Total liabilities and stockholders’ equity	$ 972,933	$ 985,850

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Long-term debt, net of debt discount	$ 3,085	$ 3,922
Allowance for doubtful accounts receivables	$ 12,313	$ 0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	278,000,000	278,000,000
Common stock, shares issued	129,195,000	127,604,000
Common stock, shares outstanding	129,194,842	127,604,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 69,514	$ 167,735	$ 176,688	$ 538,191
Operating expenses:
Cost of sales - product	13,229	61,334	41,478	184,665
Research and development	14,116	12,962	40,767	33,746
Selling, general and administrative	38,053	32,042	111,667	100,393
Gain on sale of assets (Note 5)	(1,000)	0	(1,000)	(1,000)
Bad debt expense	0	0	12,313	0
Total operating expenses	64,398	106,338	205,225	317,804
Income from operations	5,116	61,397	(28,537)	220,387
Other income (expense):
Interest income	8,462	2,562	22,437	3,588
Interest expense	(1,691)	(1,685)	(5,065)	(5,048)
Sublease income	1,993	2,026	5,584	5,660
Change in fair value of warrant liability (Note 10)	0	0	0	1,801
Other	266	(208)	218	(63)
Net income before income taxes	14,146	64,092	(5,363)	226,325
Provision for income taxes	147	(283)	(1,245)	(902)
Net income	$ 14,293	$ 63,809	$ (6,608)	$ 225,423
Net income per share attributable to common stockholders
Basic	$ 0.11	$ 0.5	$ (0.05)	$ 1.79
Diluted	$ 0.1	$ 0.43	$ (0.05)	$ 1.51
Weighted-average shares used in computing net income per share attributable to common stockholders:
Basic	128,988	127,062	128,515	125,997
Diluted	154,196	151,538	128,515	150,433
Product
Revenues:
Total revenues	$ 62,318	$ 163,815	$ 162,209	$ 531,462
Other Revenue
Revenues:
Total revenues	$ 7,196	$ 3,920	$ 14,479	$ 6,729

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 14,293	$ 63,809	$ (6,608)	$ 225,423
Other comprehensive income (loss), net of tax:
Change in unrealized loss on marketable securities available-for-sale	426	(395)	(105)	(2,296)
Cumulative foreign currency translation adjustments	(1,013)	(2,307)	(416)	(4,700)
Total other comprehensive (loss) income	(587)	(2,702)	(521)	(6,996)
Total comprehensive income (loss)	$ 13,706	$ 61,107	$ (7,129)	$ 218,427

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Preferred Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning Balances at Dec. 31, 2021	$ 222,374	$ 123	$ 0	$ 1,441,868	$ (2,266)	$ (1,217,351)
Beginning Balances (in shares) at Dec. 31, 2021		122,945	0
Issuance of common stock upon exercise of warrants	24,670	$ 2		24,668
Issuance of common stock upon exercise of warrants (Shares)		1,879
Issuance of common stock upon exercise of stock options	9,487	$ 1		9,486
Issuance of common stock upon exercise of stock options (in shares)		1,171
Issuance of common stock upon release of restricted stock awards		$ 1		(1)
Issuance of common stock upon release of restricted stock awards (in shares)		1,432
Issuance of common stock under Employee Stock Purchase Plan	1,430			1,430
Issuance of common stock under Employee Stock Purchase Plan (in shares)		154
Stock compensation expense	24,188			24,188
Total other comprehensive income (Loss)	(6,996)				(6,996)
Net Income (Loss)	225,423					225,423
Ending Balances at Sep. 30, 2022	500,576	$ 127	$ 0	1,501,639	(9,262)	(991,928)
Ending Balances (in shares) at Sep. 30, 2022		127,581	0
Beginning Balances at Jun. 30, 2022	422,799	$ 126	$ 0	1,484,970	(6,560)	(1,055,737)
Beginning Balances (in shares) at Jun. 30, 2022		126,439	0
Issuance of common stock upon exercise of stock options	7,337	$ 1		7,336
Issuance of common stock upon exercise of stock options (in shares)		884
Issuance of common stock upon release of restricted stock awards (in shares)		186
Issuance of common stock under Employee Stock Purchase Plan	720			720
Issuance of common stock under Employee Stock Purchase Plan (in shares)		72
Stock compensation expense	8,613			8,613
Total other comprehensive income (Loss)	(2,702)				(2,702)
Net Income (Loss)	63,809					63,809
Ending Balances at Sep. 30, 2022	500,576	$ 127	$ 0	1,501,639	(9,262)	(991,928)
Ending Balances (in shares) at Sep. 30, 2022		127,581	0
Beginning Balances at Dec. 31, 2022	581,013	$ 128	$ 0	1,510,518	(5,438)	(924,195)
Beginning Balances (in shares) at Dec. 31, 2022		127,604	0
Issuance of common stock upon exercise of stock options	4,339			4,339
Issuance of common stock upon exercise of stock options (in shares)		556
Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings	(6,125)	$ 1		(6,126)
Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings (in shares)		874
Issuance of common stock under Employee Stock Purchase Plan	1,535			1,535
Issuance of common stock under Employee Stock Purchase Plan (in shares)		161
Stock compensation expense	31,283			31,283
Total other comprehensive income (Loss)	(521)				(521)
Net Income (Loss)	(6,608)					(6,608)
Ending Balances at Sep. 30, 2023	604,916	$ 129	$ 0	1,541,549	(5,959)	(930,803)
Ending Balances (in shares) at Sep. 30, 2023		129,195	0
Beginning Balances at Jun. 30, 2023	577,205	$ 129	$ 0	1,527,544	(5,372)	(945,096)
Beginning Balances (in shares) at Jun. 30, 2023		128,779	0
Issuance of common stock upon exercise of stock options	2,722			2,722
Issuance of common stock upon exercise of stock options (in shares)		312
Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings	$ (162)			$ (162)
Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings (in shares)		24
Issuance of common stock under Employee Stock Purchase Plan (in shares)	758	80		758
Stock compensation expense	$ 10,687			$ 10,687
Total other comprehensive income (Loss)	(587)				(587)
Net Income (Loss)	14,293					14,293
Ending Balances at Sep. 30, 2023	$ 604,916	$ 129	$ 0	$ 1,541,549	$ (5,959)	$ (930,803)
Ending Balances (in shares) at Sep. 30, 2023		129,195	0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities
Net Income (Loss)	$ (6,608)	$ 225,423
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization	3,228	2,975
Amortization of right-of-use assets and loss on disposal of property and equipment	2,090	2,244
Accretion of discounts on marketable securities	(11,313)	(1,969)
Change in fair value of warrant liability	0	(1,801)
Stock compensation expense	31,283	24,188
Bad debt expense (Note 6)	12,313	0
Non-cash interest expense	2,246	2,222
Inventory write-off	0	14,485
Gain on sale of assets (Note 5)	(1,000)	(1,000)
Changes in operating assets and liabilities:
Accounts and other receivables, net	40,935	698
Inventories	9,435	(55,759)
Prepaid manufacturing	0	146,928
Prepaid expenses and other current assets	(4,650)	(26,240)
Other assets	730	61
Accounts payable	(612)	301
CEPI accrual (Note 6)	0	(21,110)
Lease liabilities	(2,635)	(2,366)
Deferred revenue	0	(262,469)
Accrued liabilities and other liabilities	11,355	(19,043)
Net cash provided by (used in) operating activities	86,797	27,768
Investing activities
Purchases of marketable securities	(484,040)	(514,676)
Proceeds from maturities of marketable securities	351,735	236,200
Purchases of property and equipment, net	(2,381)	(5,552)
Proceeds from sale of assets	1,000	1,000
Net cash used in investing activities	(133,686)	(283,028)
Financing activities
Proceeds from warrants exercises	0	8,455
Proceeds from exercise of stock options and/or release of restricted stock awards, net	4,339	9,487
Proceeds from Employee Stock Purchase Plan	1,535	1,430
Payments for taxes related to net share settlement of RSUs	(6,264)	0
Net cash provided by financing activities	(390)	19,372
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(155)	(1,755)
Net (decrease) increase in cash, cash equivalents and restricted cash	(47,434)	(237,643)
Cash, cash equivalents and restricted cash at beginning of period	202,211	436,408
Cash, cash equivalents and restricted cash at end of period	154,777	198,765
Supplemental disclosure of cash flow information
Cash paid during the period for income taxes	1,413	788
Cash paid during the period for interest	2,819	2,819
Reclassification of contract asset from other current assets to other assets	71,307	0
Reclassification of CEPI accrual to CEPI accrual long-term	(60,337)	0
Advance Payments forgiven per CEPI-Bio E Assignment Agreement (Note 6)	(47,401)	0
Non-cash investing and financing activities:
Purchases of property and equipment, not yet paid	704	973
Right-of-use assets obtained in exchange of lease liabilities	$ 1,332	$ 2,475

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 14,293	$ 63,809	$ (6,608)	$ 225,423

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
Organization and Summary of Significant Accounting Policies	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”) is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] is approved in the United States, the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older. In May 2022, we commenced commercial shipments of HEPLISAV-B in Germany. We also manufacture and sell CpG 1018®, the adjuvant used in HEPLISAV-B, and have established a portfolio of global commercial supply agreements in the development of COVID-19 vaccines across a variety of vaccine platforms utilizing CpG 1018 adjuvant. As of September 30, 2023, we have satisfied all delivery obligations under these global commercial supply agreements. We are also advancing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs including Phase 1 clinical trials for Tdap and shingles, and a Phase 2 clinical trial and studies for plague in collaboration with and fully funded by the U.S. Department of Defense ("DoD"). Additionally, we are working to advance product candidates utilizing our CpG 1018 adjuvant through discovery efforts and through preclinical and clinical collaborations with third-party research organizations. Basis of Presentation Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which we consider necessary to present fairly our financial position and the results of our operations and cash flows. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted. Interim-period results are not necessarily indicative of results of operations or cash flows to be expected for a full-year period or any other interim-period. The condensed consolidated balance sheet as of December 31, 2022 has been derived from audited financial statements at that date, but excludes some disclosures required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements and these notes should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 , as filed with the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of Dynavax and our wholly-owned subsidiaries, Dynavax GmbH, located in Düsseldorf, Germany, Dynavax India LLP, located in India, and a branch of Dynavax registered in Italy. All significant intercompany accounts and transactions among these entities have been eliminated from the unaudited condensed consolidated financial statements. We operate in one business segment: discovery, development and commercialization of novel vaccines. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that may affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes, including amounts of revenues and expenses during the reported periods. Management’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates, judgments and methodologies. Significant estimates and assumptions in the unaudited condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets; valuation procedures for right-of-use assets and operating lease liabilities; valuation of inventory; research and development expenses; contingencies and share-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Recent Accounting Pronouncements Accounting Standards Update 2016-13 In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments , which was codified in Accounting Standards Codification (“ASC”) 326, Financial Instruments — Credit Losses (“ASC 326"). The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for us for fiscal years beginning after December 15, 2022. As such, we adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, we updated our impairment model to utilize a forward-looking current expected credit losses (“CECL”) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including our accounts receivable and contract asset. In relation to available-for-sale (“AFS") debt securities, the guidance eliminates the concept of “other-than-temporary” impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our unaudited condensed consolidated financial statements as of the adoption date.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. Fair Value Measurements We measure fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: • Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities; • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. There were no transfers between Level 1, 2 and 3 during each of the three and nine months ended September 30, 2023. The carrying amounts of cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature. Recurring Fair Value Measurements The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands): Level 1 Level 2 Level 3 Total September 30, 2023 Assets Money market funds $ 131,837 $ - $ - $ 131,837 U.S. treasuries - 51,589 - 51,589 U.S. government agency securities - 189,312 - 189,312 Corporate debt securities - 325,756 - 325,756 Total assets $ 131,837 $ 566,657 $ - $ 698,494 Level 1 Level 2 Level 3 Total December 31, 2022 Assets Money market funds $ 172,418 $ - $ - $ 172,418 U.S. treasuries - 42,308 - 42,308 U.S. government agency securities - 88,032 - 88,032 Corporate debt securities - 292,051 - 292,051 Total assets $ 172,418 $ 422,391 $ - $ 594,809 Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. U.S. treasuries, U.S. government agency securities and corporate debt securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

Cash, Cash Equivalents, Restric

Cash, Cash Equivalents, Restricted Cash and Marketable Securities	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Cash, Cash Equivalents, Restricted Cash and Marketable Securities	3. Cash and Cash Equivalents, Restricted Cash and Marketable Securities The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, December 31, September 30, December 31, Cash and cash equivalents $ 154,511 $ 202,004 $ 198,576 $ 436,189 Restricted cash (1) 266 207 189 219 Total cash and cash equivalents, and restricted cash shown $ 154,777 $ 202,211 $ 198,765 $ 436,408 (1) Restricted cash is included in "Other assets" in the Condensed Consolidated Balance Sheets. Restricted cash balances relate to certificates of deposit issued as collateral to certain letters of credit issued as security to our facility leases (see Note 5). Cash and cash equivalents and marketable securities consist of the following (in thousands): Amortized Unrealized Unrealized Estimated September 30, 2023 Cash and cash equivalents: Cash $ 21,922 $ - $ - $ 21,922 Money market funds 131,837 - - 131,837 Corporate debt securities 752 - - 752 Total cash and cash equivalents 154,511 - - 154,511 Marketable securities available-for-sale: U.S. treasuries 51,734 - ( 145 ) 51,589 U.S. government agency securities 190,323 - ( 1,011 ) 189,312 Corporate debt securities 325,360 6 ( 362 ) 325,004 Total marketable securities available-for-sale 567,417 6 ( 1,518 ) 565,905 Total cash and cash equivalents, and marketable securities $ 721,928 $ 6 $ ( 1,518 ) $ 720,416 December 31, 2022 Cash and cash equivalents: Cash $ 29,586 $ - $ - $ 29,586 Money market funds 172,418 - - 172,418 Total cash and cash equivalents 202,004 - - 202,004 Marketable securities available-for-sale: U.S. treasuries 42,502 - ( 194 ) 42,308 U.S. government agency securities 88,429 - ( 397 ) 88,032 Corporate debt securities 292,865 12 ( 826 ) 292,051 Total marketable securities available-for-sale 423,796 12 ( 1,417 ) 422,391 Total cash and cash equivalents, and marketable securities $ 625,800 $ 12 $ ( 1,417 ) $ 624,395 The maturities of our marketable securities available-for-sale are as follows (in thousands): September 30, 2023 Amortized Estimated Mature in one year or less $ 494,498 $ 493,376 Mature after one year through two years 72,919 72,529 $ 567,417 $ 565,905 We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities. Unrealized losses are included in accumulated other comprehensive loss in stockholders’ equity. Commencing with our adoption of ASC 326 on January 1, 2023, we determine whether a decline in the fair value of our AFS debt securities below their amortized cost basis (i.e., an impairment) is due to credit-related factors or noncredit-related factors. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. Credit-related impairments (if any) are recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Both the allowance and the adjustment to net income can be reversed if conditions change. There we re no realized gains or losses from the sale of marketable securities during each of the three and nine months ended September 30, 2023 and 2022. We do not intend to sell, and are not required to sell, the investments that are in an unrealized loss position before recovery of their amortized cost basis. During each of the three and nine months ended September 30, 2023, we did not record an allowance for credit losses, as management believes any such losses would be immaterial based on the investment-grade credit rating for each of the investments as of September 30, 2023. As such, there have been no declines in fair value that have been identified as a credit-related impairment.

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories The following table presents inventories (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 27,469 $ 25,517 Work-in-process 17,515 23,934 Finished goods 4,428 9,995 Total $ 49,412 $ 59,446

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Leases We lease our facilities in Emeryville, California and Düsseldorf, Germany. We lease and sublease certain manufacturing and office space with lease terms ranging from 3 to 12 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include options to renew or extend the lease for two successive five-year terms . These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these leases as we did not consider the exercise of these options to be reasonably certain. We also sublease one of our leased premises to a third party. Rent is subject to scheduled annual increases and the subtenant is responsible for certain operating expenses and taxes throughout the life of the sublease. The sublease term expires on March 31, 2031 , unless earlier terminated, concurrent with the term of our lease. The subtenant has no option to extend the sublease term . Sublease income for the three and nine months ended September 30, 20 23 was $ 2.0 million and $ 5.6 million, r espectively. Sublease income for the three and nine months ended September 30, 2022 was $ 2.0 million and $ 5.7 million, respectively. Sublease income is included in other income (expense) in our condensed consolidated statements of operations. Rent received from the subtenant in excess of rent paid to the landlord shall be shared by paying the landlord 50 % of the excess rent. The excess rent is considered a variable lease payment and the total estimated payments are being recognized as additional rent expense on a straight-line basis. Our lease expense comprises of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease expense $ 1,392 $ 1,377 $ 4,172 $ 4,851 Cash paid for amounts included in the measurement of lease liabilities for each of the nine months ended September 30, 2023 and 2022 was $ 5.3 million and $ 5.1 million, respectively, and were included in change in lease liabilities in our condensed consolidated statements of cash flows. The balance sheet classification of our operating lease liabilities was as follows (in thousands): September 30, 2023 December 31, 2022 Operating lease liabilities: Current portion of lease liabilities (included in other current liabilities) $ 4,390 $ 3,631 Long-term portion of lease liabilities 30,680 32,801 Total operating lease liabilities $ 35,070 $ 36,432 As of September 30, 2023, the maturities of our sublease income and operating lease liabilities were as follows (in thousands): Years ending December 31, Sublease Income Operating Lease 2023 (remaining) $ 1,405 $ 1,873 2024 5,684 7,579 2025 5,854 6,954 2026 6,030 6,096 2027 6,211 6,026 Thereafter 21,500 21,171 Total $ 46,684 49,699 Less: Present value adjustment ( 14,629 ) Total $ 35,070 The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows: September 30, 2023 December 31, 2022 Weighted average remaining lease term 6.8 years 7.6 years Weighted average discount rate 10.1 % 10.1 % Commitments As of September 30, 2023 and December 31, 2022, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled $ 39.8 million and $ 43.4 million, respectively. On September 7, 2023 (the “Effective Date”), we entered into an agreement (the “Avecia Supply Agreement”) with Nitto Denko Avecia Inc. (“Avecia”) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the “2012 Agreement”). As of September 30, 2023, we have not placed any manufacturing orders under the Avecia Supply Agreement. As of September 30, 2023 and December 31, 2022, we have no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant . As of September 30, 2023, the aggregate principal amount of our convertible senior notes ("Convertible Notes") was $ 225.5 million, excluding debt discount of $ 3.1 million (see Note 7). During 2004, we established a letter of credit with Deutsche Bank as security for our Düsseldorf lease in the amount of € 0.2 million (Euros). The letter of credit remained outstanding through September 30, 2023 and was collateralized by a certificate of deposit for € 0.2 million, which has been included in restricted cash in the condensed consolidated balance sheets as of September 30, 2023. In conjunction with our agreement with Symphony Dynamo, Inc. and Symphony Dynamo Holdings LLC (“Holdings”) in November 2009, we agreed to make contingent cash payments to Holdings equal to 50 % of the first $ 50 million from any upfront, pre-commercialization milestone or similar payments received by us from any agreement with any third party with respect to the development and/or commercialization of cancer and hepatitis C therapies originally licensed to Symphony Dynamo, Inc., including our immune-oncology compound, SD-101. In July 2020, we sold assets related to SD-101 to Surefire Medical, Inc. d/b/a TriSalus Life Sciences (“TriSalus”). We paid $ 2.5 million to Holdings in August 2020. In each of September 2021, May 2022 and September 2023, we received $ 1.0 million from TriSalus because it met pre-commercialization milestones. We recorded the proceeds as gain on sale of assets in our condensed consolidated statements of operations. We paid Holdings $ 0.5 million in each of September 2021, May 2022 and October 2023. We included the payments in selling, general and administrative expenses in our condensed consolidated statements of operations. A liability of $ 0.5 million has been recorded under this agreement as of September 30, 2023 in relation to our payment to Holdings in October 2023. Contingencies From time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, results of operations, or cash flows in a particular period.

Collaborative Research, Develop

Collaborative Research, Development and License Agreements	9 Months Ended
Collaborative Research, Development and License Agreements	Sep. 30, 2023
Research and Development [Abstract]
Collaboration, Development and Supply Agreements	6. Collaboration, Development and Supply Agreements Coalition for Epidemic Preparedness Innovations In January 2021, we entered into an agreement (together with subsequent amendments, the “CEPI Agreement”) with Coalition for Epidemic Preparedness Innovations (“CEPI”) for the manufacture and reservation of a specified quantity of CpG 1018 adjuvant (“CpG 1018 Materials”). In May 2021, we entered into the first amendment to the CEPI Agreement. The CEPI Agreement enables CEPI to direct the supply of CpG 1018 Materials to CEPI partner(s). CEPI partner(s) would purchase CpG 1018 Materials under separately negotiated agreements. The CEPI Agreement also allows us to sell CpG 1018 Materials to third parties if not purchased by a CEPI partner within a two-year term. In exchange for reserving CpG 1018 Materials and agreeing to sell CpG 1018 Materials to CEPI partner(s) at pre-negotiated prices, CEPI agreed to provide payments in the form of an interest-free, unsecured, forgivable loan (the “Advance Payments”). We are obligated to repay the Advance Payments, in proportion to quantity sold, if and to the extent we receive payments from sales of CpG 1018 Materials reserved under the CEPI Agreement. If the vaccine programs pursued by CEPI partner(s) are unsuccessful and no alternative use is found for CpG 1018 Materials reserved under the CEPI Agreement, the applicable Advance Payments will be forgiven at the end of the two-year term. On April 27, 2023, we entered into a waiver and second amendment to the CEPI Agreement by and between us and CEPI (the “CEPI-Bio E Assignment Agreement”). Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of the outstanding Advance Payments for CpG 1018 Materials allocated to and ordered by Bio E under the CEPI Agreement and has assumed our previous rights to $ 47.4 million of Bio E accounts receivable. Through September 30, 2023, we received Advance Payments totaling approximately $ 175.0 mill ion pursuant to the CEPI Agreement, of which $ 67.3 million have been repaid and $ 47.4 million have been forgiven (as discussed above). As of September 30, 2023, remaining Advance Payments totaling $ 60.3 million in CEPI accrual long-term were reflected in our condensed consolidated balance s heets, representing the outstanding balance of the Advance Payments relating to the Clover Supply Agreement (as defined and discussed below). As of December 31, 2022, we recorded Advance Payments of $ 107.7 million included in CEPI accrual. There were no deferred revenue balances related to the CEPI Agreement as of September 30, 2023 and December 31, 2022. Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited In June 2021, we entered into an agreement with Zhejiang Clover Biopharmaceuticals, Inc. and Clover Biopharmaceuticals (Hong Kong) Co., Limited (collectively, “Clover”), for the commercial supply of CpG 1018 adjuvant, for use with Clover’s COVID-19 vaccine candidate, SCB-2019 (together with subsequent amendments, the “Clover Supply Agreement”). Under the Clover Supply Agreement, Clover committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Clover’s commercialization of vaccines containing SCB-2019 and CpG 1018 adjuvant (“Clover Product”). The Clover Supply Agreement also provides terms for Clover to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In 2022 and 2023, we signed four amendments to the Clover Supply Agreement. The terms and conditions of the Clover Supply Agreement were operative through December 2022, and as of September 30, 2023, we had satisfied all delivery obligations thereunder. For CpG 1018 adjuvant reserved for Clover under the CEPI Agreement, Clover is obligated to pay us the purchase price upon the earliest of (i) the true-up exercise, (ii) within a specified period after Clover delivers Clover Product to a customer, or (iii) Clover’s receipt of payment for Clover Product from a customer. When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement, we recognize product revenue and a corresponding contract asset as our right to consideration is contingent on something other than the passage of time, as outlined above. The contract asset of $ 71.3 million relating to Clover was included in other current assets as of December 31, 2022. The contract asset was subsequently reclassified to other assets (long term) and remains classified in other assets (long term) as of September 30, 2023. The contract asset was reclassified to other assets (long term) to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. Corresponding Advance Payments of $ 60.3 million relating to Clover are recorded in CEPI accrual long-term in our condensed consolidated balance sheets as of September 30, 2023. These Advance Payments may be repaid using cash collected from Clover or forgiven in accordance with the CEPI Agreement. We had no ac counts receivable balance from Clover as of September 30, 2023 and December 31, 2022. We did no t recognize CpG 1018 adjuvant net product revenue from Clover for each of the three and nine months ended September 30, 2023. W e recognized CpG 1018 adjuvant product revenue, net of $ 87.5 million and $ 201.1 million, respectively, for each of the three and nine months ended September 30, 2022. Biological E. Limited In July 2021, we entered into an agreement (together with subsequent amendments, the “Bio E Supply Agreement”) with Biological E. Limited (“Bio E”), for the commercial supply of CpG 1018 adjuvant, for use with Bio E’s subunit COVID-19 vaccine candidate, CORBEVAX. Under the Bio E Supply Agreement, Bio E committed to purchase specified quantities of CpG 1018 adjuvant, at pre-negotiated prices pursuant to the CEPI Agreement, for use in Bio E’s commercialization of its CORBEVAX vaccine (“Bio E Product”) with specified delivery dates in 2021 and the first quarter of 2022. The Bio E Supply Agreement also provides terms for Bio E to order additional quantities of CpG 1018 adjuvant beyond the quantities reserved by CEPI. In June 2022 and in October 2022, we entered into amendments to the Bio E Supply Agreement (the “Bio E Amendment No. 1” and the “Bio E Amendment No. 2,” together the “Bio E Amendments”). The Bio E Amendments primarily established: (i) a new payment schedule for certain outstanding invoices related to the CEPI product to be the earlier of December 31, 2022, or receipt of certain amounts from Bio E from the Government of India in connection with their advance purchase agreement for CORBEVAX, and (ii) further modified the scope of the Bio E Supply Agreement, by reducing certain quantities of CpG 1018 adjuvant to be delivered. The terms and conditions of the Bio E Supply Agreement were operative through December 2022, and as of September 30, 2023, we had satisfied all delivery obligations thereunder. As of September 30, 2023, we had no accounts receivable balance from Bio E. During the first quarter of 2023, we recorded an allowance for doubtful accounts of $ 12.3 million, which was determined by assessing changes in Bio E’s credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (defined below), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. On April 26, 2023, we entered into a third amendment to the Bio E Supply Agreement (the “Bio E Amendment No. 3”), and on April 27, 2023, we entered into the CEPI-Bio E Assignment Agreement. Pursuant to the CEPI-Bio E Assignment Agreement, CEPI has forgiven the entirety of remaining amounts outstanding relating to a liability for Advance Payments of $ 47.4 million (the “Bio E CEPI Advance Payments”) for CpG 1018 Materials allocated to Bio E, and has assumed our previous rights to collect $ 47.4 million of Bio E accounts receivable. Pursuant to the Bio E Amendment No. 3, we collected $ 14.5 million from Bio E (including $ 13.5 million in April 2023 and $ 1.0 million in August 2023). Accordingly, as of September 30, 2023, the CEPI-Bio E Assignment Agreement resulted in: (i) no accounts receivable balance, and (ii) the derecognition of $ 47.4 million CEPI accrual in connection with the Bio E CEPI Advance Payments. The Bio E Amendment No. 3 provides for additional future payment of either $ 5.5 million in the event that Bio E receives at least $ 125.0 million, or $ 12.3 million in the event that Bio E receives at least $ 250.0 million in future payments from the Government of India associated with its CORBEVAX product on or before August 15, 2025. These additional amounts are not considered collectible until the achievement of these future milestones. We did no t recognize CpG 1018 adjuvant net product revenue from Bio E for each of the three and nine months ended September 30, 2023. We recognized CpG 1018 adjuvant net product revenue of $ 27.6 million and $ 146.0 million for the three and nine months ended September 30, 2022, respectively. U.S. Department of Defense In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine adjuvanted with CpG 1018 adjuvant for approximately $ 22.0 million over two and a half years. Under the agreement, we are conducting a Phase 2 clinical trial combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. In July 2023, we executed a contract modification with the DoD to support advancement into a nonhuman primate challenge study, with the agreement now totaling $ 33.7 million through 2025. For the three and nine months ended September 30, 2023, we recognized revenue o f $ 7.2 million and $ 14.5 million, respectively, which is included in other revenue in our condensed consolidated statements of operations. For the three and nine months ended September 30, 2022, we recognized revenue of $ 3.9 million and $ 6.6 million, respectively.

Convertible Notes

Convertible Notes	9 Months Ended
Convertible Notes	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Notes	7. Convertible Notes In May 2021, we issued $ 225.5 million of Convertible Notes in a private placement. Total proceeds from the issuance of the Convertible Notes, net of debt issuance and offering costs of $ 5.7 million, were $ 219.8 million. We used $ 190.2 million of the net proceeds to retire our previous loan agreement with CRG Servicing LLC and $ 27.2 million of the net proceeds to pay the costs of the Capped Calls described below. The Convertible Notes are general, unsecured obligations and accrue interest at a rate of 2.50% per annum payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021. The Convertible Notes mature on May 15, 2026 , unless converted, redeemed or repurchased prior to such date. The Convertible Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, at an initial conversion rate of 95.5338 shares of our common stock per $ 1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $ 10.47 per share of our common stock. The Convertible Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding February 15, 2026, only under the following circumstances: • During any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130 % of the conversion price on each applicable trading day; • During the five business day period after any ten consecutive trading day period (the “measurement period”), in which the “trading price” (as defined the indenture governing the Convertible Notes) per $ 1,000 principal amount of the Convertible Notes for each trading day of the measurement period was less than 98 % of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; • If we call such Convertible Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or • Upon the occurrence of specified corporate events as set forth in the indenture governing the Convertible Notes. On or after February 15, 2026, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Convertible Notes may convert all or any portion of their Convertible Notes regardless of the foregoing circumstances. On October 1, 2023, the conditional conversion feature of the Convertible Notes was triggered as the last reported sale price of our common stock was more than or equal to 130 % of the conversion price for at least 20 trading days in the period of 30 consecutive trading days ending on September 30, 2023 (the last trading day of the immediately preceding fiscal quarter), and therefore the Convertible Notes are currently convertible, in whole or in part, at the option of the holders between October 1, 2023 through December 31, 2023. Whether the Convertible Notes will be convertible following such period will depend on the continued satisfaction of this condition or another conversion condition in the future. As of November 2, 2023, we had not received any conversion notices. Since we have the election of repaying the Convertible Notes in cash, shares of our common stock, or a combination of both, we continued to classify the Convertible Notes as long-term debt on the condensed consolidated balance sheets as of September 30, 2023. We may redeem for cash all or any portion of the Convertible Notes (subject to the partial redemption limitation described in the indenture governing the Convertible Notes), at our option, on or after May 20, 2024 and prior to the 31st scheduled trading day immediately preceding the maturity date, if the last reported sale price of our common stock has been at least 130 % of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100 % of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If we undergo a fundamental change (as set forth in the indenture governing the Convertible Notes), noteholders may require us to repurchase for cash all or any portion of their Convertible Notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events (as set forth in the indenture governing the Convertible Notes) or if we deliver a notice of redemption prior to the maturity date, we will, in certain circumstances, adjust the conversion rate for a noteholder who elects to convert its notes in connection with such a corporate event or such notice of redemption. We accounted for the Convertible Notes as a single liability in accordance with ASU 2020-06 - Accounting for Convertible Instruments and Contracts in an Entity's Own Equity (“ASU 2020-06”). As of September 30, 2023, the Convertible Notes were recorded at the aggregate principal amount of $ 225.5 million less unamortized issuance costs of $ 3.1 million as a long-term liability on the condensed consolidated balance sheets. As of September 30, 2023, the fair value of the Convertible Notes was $ 344.8 million. The fair value was estimated using a reputable third-party valuation model based on observable inputs and is considered Level 2 in the fair value hierarchy. The debt issuance costs are amortized to interest expense over the contractual term of the Convertible Notes at an effective interest rate of 3.1 %. The following table presents the components of interest expense related to Convertible Notes (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Stated coupon interest $ 1,409 $ 1,409 $ 4,227 $ 4,228 Amortization of debt issuance cost 282 273 838 812 Total interest expense $ 1,691 $ 1,682 $ 5,065 $ 5,040 Capped Calls In connection with the issuance of the Convertible Notes, we entered into capped call transactions with one of the initial purchasers of the Convertible Notes and other financial institutions, totaling $ 27.2 million (the “Capped Calls”). The Capped Calls cover, subject to customary adjustments, the number of shares of our common stock that initially underlie the Convertible Notes (or 21,542,871 shares of our common stock). The Capped Calls have an initial strike price and an initial cap price of $ 10.47 per share and $ 15.80 per share, respectively, subject to certain adjustments. Conditions that cause adjustments to the initial strike price of the Capped Calls mirror conditions that result in corresponding adjustments to the conversion price of the Convertible Notes. The Capped Calls are expected to offset the potential dilution to our common stock as a result of any conversion of the Convertible Notes, subject to a cap based on the cap price. For accounting purposes, the Capped Calls are considered separate financial instruments and not part of the Convertible Notes. As the Capped Calls transactions meet certain accounting criteria, we recorded the cost of the Capped Calls, totaling $ 27.2 million, as a reduction to additional paid-in capital within the condensed consolidated statements of stockholders’ equity.

Revenue Recognition

Revenue Recognition	9 Months Ended
Revenue Recognition	Sep. 30, 2023
Revenue Recognition [Abstract]
Revenue Recognition	8. Revenue Recognition Disaggregation of Revenues The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands): Three Months Ended Three Months Ended September 30, 2023 September 30, 2022 U.S. Non U.S. Total U.S. Non U.S. Total Product revenue, net HEPLISAV-B $ 62,318 $ - $ 62,318 $ 37,508 $ - $ 37,508 CpG 1018 adjuvant - - - - 126,307 126,307 Total product revenue, net $ 62,318 $ - $ 62,318 $ 37,508 $ 126,307 $ 163,815 Other revenue 7,196 - 7,196 3,877 43 3,920 Total revenues $ 69,514 $ - $ 69,514 $ 41,385 $ 126,350 $ 167,735 Nine Months Ended Nine Months Ended September 30, 2023 September 30, 2022 U.S. Non U.S. Total U.S. Non U.S. Total Product revenue, net HEPLISAV-B $ 162,209 $ - $ 162,209 $ 90,057 $ 941 $ 90,998 CpG 1018 adjuvant - - - - 440,464 440,464 Total product revenue, net $ 162,209 $ - $ 162,209 $ 90,057 $ 441,405 $ 531,462 Other revenue 14,479 - 14,479 6,566 163 6,729 Total revenues $ 176,688 $ - $ 176,688 $ 96,623 $ 441,568 $ 538,191 Revenues from Major Customers and Collaboration Partners All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs and retail pharmacies. All of our HEPLISAV-B sales in Germany are to one distributor. The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Largest customer 27 % 23 % 25 % 20 % Second largest customer 25 % 19 % 24 % 18 % Third largest customer 18 % 18 % 17 % 17 % The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant net product revenue): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Largest collaboration partner 0 % 69 % 0 % 46 % Second largest collaboration partner 0 % 22 % 0 % 33 % Third largest collaboration partner 0 % 9 % 0 % 15 % Contract Balances The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the nine months ended September 30, 2023 (in thousands): Balance at Provisions Credit or Adjustments related to prior periods Balance Nine months ended September 30, 2023: Accounts receivable reserves (1) $ 8,179 $ 42,949 $ ( 40,186 ) $ ( 2,629 ) $ 8,313 Revenue reserve accruals (2) $ 10,552 $ 34,848 $ ( 27,528 ) $ 2,297 $ 20,169 (1) Reserves are for chargebacks, discounts and other fees. (2) Accruals are for returns, rebates and other fees. When we transfer control of CpG 1018 adjuvant that is reserved under the CEPI Agreement to Clover and perform services under our agreement with the DoD, we recognize revenue and a corresponding contract asset as our right to consideration is conditioned on something other than the passage of time. See Note 6 for further discussion. The following table summarizes balances and activities in our contract asset account (in thousands): Balance at Additions Subtractions Reclassification (1) Balance Nine months ended September 30, 2023: Contract asset, included in other current assets (2) $ 71,965 $ 14,396 $ ( 13,175 ) $ ( 71,307 ) $ 1,879 Contract asset, included in other assets (long term) $ - $ - $ - $ 71,307 $ 71,307 (1) The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 6 for further discussion. (2) The $1.9 million of contract asset is derived from our agreement with the DoD.

Net Income Per Share

Net Income Per Share	9 Months Ended
Net Income Per Share	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Income Per Share	9. Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of our common stock outstanding. For the calculation of diluted net income per share, net income attributable to common stockholders for basic net income per share is adjusted by the effect of dilutive securities, including awards under our equity compensation plans and change in fair value of warrant liability. Diluted net income per share attributable to common stockholders is computed by dividing the resulting net income attributable to common stockholders by the weighted-average number of fully diluted common shares outstanding. The numerators and denominators of the basic net income (loss) and diluted net income per share computations for our common stock are calculated as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Numerator Net income (loss) $ 14,293 $ 63,809 $ ( 6,608 ) $ 225,423 Less: undistributed earnings allocated to participating securities - - - ( 291 ) Net income (loss) attributable to common stockholders, basic 14,293 63,809 ( 6,608 ) 225,132 Add: undistributed earnings allocated to participating securities - - - 291 Less: removal of change in fair value of warrant liability - - - ( 1,801 ) Add: interest expense on convertible notes 1,268 1,262 - 3,780 Net income (loss) attributable to common stockholders, diluted $ 15,561 $ 65,071 $ ( 6,608 ) $ 227,402 Denominator Weighted average common stock outstanding, basic 128,988 127,062 128,515 125,997 Effect of dilutive shares: Stock-based compensation plans 3,665 2,933 - 2,784 Dilutive warrants - - - 109 Convertible Notes (as converted to common stock) 21,543 21,543 - 21,543 Weighted average common stock outstanding, diluted 154,196 151,538 128,515 150,433 The following were excluded from the calculation of diluted net income (loss) per share as the effect of their inclusion would have been anti-dilutive (in thousands). Three months ended September 30, Nine months ended September 30, 2023 2022 2023 2022 Outstanding securities not included in diluted net income (loss) per share calculation: Stock options and stock awards 5,605 5,214 15,304 7,417 Convertible Notes (as converted to common stock) - - 21,543 - Total 5,605 5,214 36,847 7,417

Common Stock and Warrants

Common Stock and Warrants	9 Months Ended
Common Stock and Warrants	Sep. 30, 2023
Preferred Stock Common Stock And Warrants [Abstract]
Common Stock and Warrants	10. Common Stock and Warrants Common Stock As of September 30, 2023, there wer e 129,194,842 sh ares of our common stock outstanding. We entered into an at-the-market Sales Agreement with Cowen and Company, LLC (“Cowen”) on August 6, 2020 and an amendment to such agreement on August 3, 2023 (the sales agreement as amended, the “2020 ATM Agreement”). Under the 2020 ATM Agreement, we may offer and sell from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $ 120.0 million through Cowen as our sales agent. We agreed to pay Cowen a commission of up to 3 % of the gross sales proceeds of any common stock sold through Cowen under the 2020 ATM Agreement. As of September 30, 2023, w e ha d approximately $ 120.0 million rema ining under the 2020 ATM Agreement. Warrants During the nine months ended September 30, 2022, all of the 1,882,600 outstanding warrants as of December 31, 2021 were exercised or expired, resulting in cash proceeds totaling $ 8.5 million. During the nine months ended September 30, 2022, we recognized the decrease in the estimated fair value of warrant liability of $ 1.8 million as income in other income (expense) in our condensed consolidated statements of operations.

Equity Plans and Stock-Based Co

Equity Plans and Stock-Based Compensation	9 Months Ended
Equity Plans and Stock-Based Compensation	Sep. 30, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Equity Plans and Stock-Based Compensation	11. Equity Plans and Stock-Based Compensation In January 2021, we adopted the Dynavax Technologies Corporation 2021 Inducement Award Plan (“2021 Inducement Plan”), pursuant to which we reserved 1,500,000 shares of common stock for issuance under the plan to be used exclusively for grants of awards to individuals who were not previously our employees or directors. In June 2021, we amended the 2021 Inducement Plan (“Amended 2021 Inducement Plan”) to increase the number of shares of common stock reserved under the 2021 Inducement Plan to 3,250,000 . The Amended 2021 Inducement Plan was terminated effective as of April 3, 2022 and, therefore, there are no shares of our common stock available for grant. In May 2022, our stockholders approved the amendment and restatement of our 2018 Equity Incentive Plan (the “Amended 2018 EIP”) to, among other things, increase the authorized number of shares of common stock by 15,000,000 . The maximum number of shares of common stock that may be issued under the Amended 2018 EIP will not exceed 32,600,000 shares of common stock. As of September 30, 2023, the Amended 2018 EIP and the Amended and Restated 2014 Employee Stock Purchase Plan are our active plans. Th e Amended 2018 EIP is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the Amended 2018 EIP have a term of seven years unless earlier terminated by the Board of Directors. As of September 30, 2023, there were 9,659,145 shares o f common stock reserved for issuance under the Amended 2018 EIP. Under our Amended 2018 EIP , we may grant stock options, RSUs, performance-based awards, and other awards that are settled in shares of our common stock. Our equity awards generally vest over a three-year period contingent upon continuous service and unless exercised, expire seven or ten years from the date of grant (or earlier upon termination of continuous service). Activity under our stock plans is set forth below: Stock Options The following table summarizes the activity of stock options for the nine months ended September 30, 2023 : Shares Weighted- Weighted- Aggregate Balance as of December 31, 2022 9,339 $ 10.70 4.61 $ 16,291 Options granted 1,968 11.14 Options exercised ( 556 ) 7.80 Options cancelled: Options forfeited (unvested) ( 83 ) 10.96 Options expired (vested) ( 260 ) 21.42 Balance as of September 30, 2023 10,408 $ 10.66 4.38 $ 46,599 Vested and expected to vest as of September 30, 2023 10,211 $ 10.65 4.35 $ 45,949 Exercisable as of September 30, 2023 6,843 $ 10.17 3.64 $ 34,772 Restricted Stock Units The following table summarizes the activity of RSUs for the nine months ended September 30, 2023 : Number of Shares Weighted-Average Non-vested as of December 31, 2022 3,479 $ 11.00 Granted 2,497 11.16 Vested (1) ( 1,456 ) 10.08 Forfeited ( 218 ) 11.49 Non-vested as of September 30, 2023 4,302 $ 11.38 (1) Inclusive of approximately 582,838 RSUs for the nine months ended September 30, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital. Market-based Performance Stock Units We granted market-based performance restricted stock units (“PSUs”) to certain executives. These PSUs vest upon a specified market condition. The summary of PSU activities for the nine months ended September 30, 2023 is as follows: Number of Shares Weighted-Average Non-vested as of December 31, 2022 193 $ 11.62 Granted 364 18.25 Non-vested as of September 30, 2023 557 $ 15.95 Performance-based Options As of September 30, 2023, approximately 36,000 s hares underlying performance-based options were outstanding. Significant Assumptions in Estimating Fair Value T he fair value of each time-based option is estimated on the date of grant using the Black-Scholes option valuation model. The fair value of each RSU is determined at the date of grant using our closing stock price. The fair value of each PSU is estimated using the Monte Carlo simulation method on the date of grant. The weighted-average assumptions used in the calculations of these fair value measurements are as follows : Stock Options Stock Options Market-Based Performance Stock Units (“PSUs”) Three Months Ended Nine Months Ended Nine Months Ended September 30, September 30, September 30, 2023 2022 2023 2022 2023 2022 Weighted-average fair value per share $ 8.61 $ - $ 7.30 $ 7.97 $ 18.25 $ 11.62 Risk-free interest rate 4.2 % - 4.0 % 2.01 % 4.3 % 1.7 % Expected life (in years) 4.5 - 4.5 4.5 2.9 2.9 Volatility 0.8 - 0.8 0.8 0.9 0.9 Stock-based Compensation Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods. We have also granted performance-based equity awards to certain of our employees. For equity awards with performance-based vest ing criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable. We recognized $ 0.7 million and $ 1.8 million of stock-based compensation expense for PSUs during the thre e and nine months ended September 30, 2023, respectively. We recog nized $ 0.2 million and $ 0.6 million of stock-based compensation expense for PSUs during the thre e and nine months ended September 30, 2022, respectively. The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our condensed consolidated statements of operations, and amounts capitalized to our inventories (in thousands ): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Research and development $ 2,339 $ 1,532 $ 6,752 $ 4,271 Selling, general and administrative 7,320 6,019 21,353 17,043 Cost of sales - product 369 323 1,463 626 Inventories 659 739 1,715 2,248 Total $ 10,687 $ 8,613 $ 31,283 $ 24,188

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes We are subject to U.S. federa l, state and foreign income taxes. For the three months ended September 30, 2023, we recorded an income tax benefit of approximately $( 0.1 ) million. For the nine months ended September 30, 2023, we recorded a provision for income taxes of approximately $ 1.2 million. Our effective tax rate was approximately ( 1.0 )% and ( 22.9 )% for the three and nine months ended September 30, 2023, respectively. For the three and nine months ended September 30, 2022, we recorded a provision for income taxes of $ 0.3 million and $ 0.9 million, respectively. Our effective tax rate was approximately 0.4 % for the nine months ended September 30, 2022. The primary difference between the effective tax rate and the federal statutory rate is due to the benefit of net operating losses utilized during the periods and the full valuation allowance we established on our federal, state, and certain foreign deferred tax assets. We have historically recorded our interim period provision for income taxes by applying our forecasted annual effective tax rate to year-to-date earnings and adjusting for discrete items. However, due to the level of forecasted provision for income taxes relative to the forecasted income used in computing the effective tax rate, the effective tax rate is highly sensitive to fluctuations in income and does not provide a reliable estimate for income taxes in the interim period. As such, we have computed our provision for income taxes for the three and nine months ended September 30, 2023 using an actual year-to-date tax calculation. We plan to revert back to applying our forecasted annual effective tax rate to year-to-date earnings and adjusting for discrete items once that method produces more reliable results. The tax benefit of net operating losses, temporary differences and credit carryforwards is required to be recorded as an asset to the extent that management assesses that realization is "more likely than not". Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. A high degree of judgment is required to determine if, and the extent to which, valuation allowances should be recorded against deferred tax assets. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Based on all available evidence as of September 30, 2023, both positive and negative, and the weight of that evidence to the extent such evidence can be objectively verified, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized, and, accordingly, has provided a valuation allowance.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which we consider necessary to present fairly our financial position and the results of our operations and cash flows. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted. Interim-period results are not necessarily indicative of results of operations or cash flows to be expected for a full-year period or any other interim-period. The condensed consolidated balance sheet as of December 31, 2022 has been derived from audited financial statements at that date, but excludes some disclosures required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements and these notes should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 , as filed with the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of Dynavax and our wholly-owned subsidiaries, Dynavax GmbH, located in Düsseldorf, Germany, Dynavax India LLP, located in India, and a branch of Dynavax registered in Italy. All significant intercompany accounts and transactions among these entities have been eliminated from the unaudited condensed consolidated financial statements. We operate in one business segment: discovery, development and commercialization of novel vaccines.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that may affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes, including amounts of revenues and expenses during the reported periods. Management’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates, judgments and methodologies. Significant estimates and assumptions in the unaudited condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets; valuation procedures for right-of-use assets and operating lease liabilities; valuation of inventory; research and development expenses; contingencies and share-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Standards Update 2016-13 In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments , which was codified in Accounting Standards Codification (“ASC”) 326, Financial Instruments — Credit Losses (“ASC 326"). The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, ASC 326 became effective for us for fiscal years beginning after December 15, 2022. As such, we adopted ASC 326 effective January 1, 2023, utilizing the modified retrospective transition method. Upon adoption, we updated our impairment model to utilize a forward-looking current expected credit losses (“CECL”) model in place of the incurred loss methodology for financial instruments measured at amortized cost, primarily including our accounts receivable and contract asset. In relation to available-for-sale (“AFS") debt securities, the guidance eliminates the concept of “other-than-temporary” impairment, and instead focuses on determining whether any impairment is a result of a credit loss or other factors. The adoption of ASC 326 did not have a material impact on our unaudited condensed consolidated financial statements as of the adoption date.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) measured at fair value on a recurring basis (in thousands): Level 1 Level 2 Level 3 Total September 30, 2023 Assets Money market funds $ 131,837 $ - $ - $ 131,837 U.S. treasuries - 51,589 - 51,589 U.S. government agency securities - 189,312 - 189,312 Corporate debt securities - 325,756 - 325,756 Total assets $ 131,837 $ 566,657 $ - $ 698,494 Level 1 Level 2 Level 3 Total December 31, 2022 Assets Money market funds $ 172,418 $ - $ - $ 172,418 U.S. treasuries - 42,308 - 42,308 U.S. government agency securities - 88,032 - 88,032 Corporate debt securities - 292,051 - 292,051 Total assets $ 172,418 $ 422,391 $ - $ 594,809

Cash, Cash Equivalents, Restr_2

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2023
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, December 31, September 30, December 31, Cash and cash equivalents $ 154,511 $ 202,004 $ 198,576 $ 436,189 Restricted cash (1) 266 207 189 219 Total cash and cash equivalents, and restricted cash shown $ 154,777 $ 202,211 $ 198,765 $ 436,408 (1) Restricted cash is included in "Other assets" in the Condensed Consolidated Balance Sheets.
Summary of Cash, Cash Equivalents and Marketable Securities	Cash and cash equivalents and marketable securities consist of the following (in thousands): Amortized Unrealized Unrealized Estimated September 30, 2023 Cash and cash equivalents: Cash $ 21,922 $ - $ - $ 21,922 Money market funds 131,837 - - 131,837 Corporate debt securities 752 - - 752 Total cash and cash equivalents 154,511 - - 154,511 Marketable securities available-for-sale: U.S. treasuries 51,734 - ( 145 ) 51,589 U.S. government agency securities 190,323 - ( 1,011 ) 189,312 Corporate debt securities 325,360 6 ( 362 ) 325,004 Total marketable securities available-for-sale 567,417 6 ( 1,518 ) 565,905 Total cash and cash equivalents, and marketable securities $ 721,928 $ 6 $ ( 1,518 ) $ 720,416 December 31, 2022 Cash and cash equivalents: Cash $ 29,586 $ - $ - $ 29,586 Money market funds 172,418 - - 172,418 Total cash and cash equivalents 202,004 - - 202,004 Marketable securities available-for-sale: U.S. treasuries 42,502 - ( 194 ) 42,308 U.S. government agency securities 88,429 - ( 397 ) 88,032 Corporate debt securities 292,865 12 ( 826 ) 292,051 Total marketable securities available-for-sale 423,796 12 ( 1,417 ) 422,391 Total cash and cash equivalents, and marketable securities $ 625,800 $ 12 $ ( 1,417 ) $ 624,395
Maturities of Marketable Securities Available-for-Sale	The maturities of our marketable securities available-for-sale are as follows (in thousands): September 30, 2023 Amortized Estimated Mature in one year or less $ 494,498 $ 493,376 Mature after one year through two years 72,919 72,529 $ 567,417 $ 565,905

Inventories, Net (Tables)

Inventories, Net (Tables)	9 Months Ended
Inventories, Net (Tables)	Sep. 30, 2023
Inventory Disclosure [Abstract]
Summary of Inventories	The following table presents inventories (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 27,469 $ 25,517 Work-in-process 17,515 23,934 Finished goods 4,428 9,995 Total $ 49,412 $ 59,446

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
Commitments and Contingencies (Tables)	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of Operating Lease Expense	Our lease expense comprises of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease expense $ 1,392 $ 1,377 $ 4,172 $ 4,851
Summary of Balance Sheet Classification of Operating Lease Liabilities	The balance sheet classification of our operating lease liabilities was as follows (in thousands): September 30, 2023 December 31, 2022 Operating lease liabilities: Current portion of lease liabilities (included in other current liabilities) $ 4,390 $ 3,631 Long-term portion of lease liabilities 30,680 32,801 Total operating lease liabilities $ 35,070 $ 36,432
Summary of Maturities of Sublease Income and Operating Lease Liabilities	As of September 30, 2023, the maturities of our sublease income and operating lease liabilities were as follows (in thousands): Years ending December 31, Sublease Income Operating Lease 2023 (remaining) $ 1,405 $ 1,873 2024 5,684 7,579 2025 5,854 6,954 2026 6,030 6,096 2027 6,211 6,026 Thereafter 21,500 21,171 Total $ 46,684 49,699 Less: Present value adjustment ( 14,629 ) Total $ 35,070
Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate	The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows: September 30, 2023 December 31, 2022 Weighted average remaining lease term 6.8 years 7.6 years Weighted average discount rate 10.1 % 10.1 %

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
Convertible Notes (Tables)	Sep. 30, 2023
Debt Disclosure [Abstract]
Summary of Interest Expenses Related to Convertible Notes	The following table presents the components of interest expense related to Convertible Notes (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Stated coupon interest $ 1,409 $ 1,409 $ 4,227 $ 4,228 Amortization of debt issuance cost 282 273 838 812 Total interest expense $ 1,691 $ 1,682 $ 5,065 $ 5,040

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
Revenue Recognition (Tables)	Sep. 30, 2023
Summary of Disaggregation of Revenues	The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands): Three Months Ended Three Months Ended September 30, 2023 September 30, 2022 U.S. Non U.S. Total U.S. Non U.S. Total Product revenue, net HEPLISAV-B $ 62,318 $ - $ 62,318 $ 37,508 $ - $ 37,508 CpG 1018 adjuvant - - - - 126,307 126,307 Total product revenue, net $ 62,318 $ - $ 62,318 $ 37,508 $ 126,307 $ 163,815 Other revenue 7,196 - 7,196 3,877 43 3,920 Total revenues $ 69,514 $ - $ 69,514 $ 41,385 $ 126,350 $ 167,735 Nine Months Ended Nine Months Ended September 30, 2023 September 30, 2022 U.S. Non U.S. Total U.S. Non U.S. Total Product revenue, net HEPLISAV-B $ 162,209 $ - $ 162,209 $ 90,057 $ 941 $ 90,998 CpG 1018 adjuvant - - - - 440,464 440,464 Total product revenue, net $ 162,209 $ - $ 162,209 $ 90,057 $ 441,405 $ 531,462 Other revenue 14,479 - 14,479 6,566 163 6,729 Total revenues $ 176,688 $ - $ 176,688 $ 96,623 $ 441,568 $ 538,191
HEPLISAV-B
Schedule of Revenues from Major Customers	The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Largest customer 27 % 23 % 25 % 20 % Second largest customer 25 % 19 % 24 % 18 % Third largest customer 18 % 18 % 17 % 17 %
Summary of Product Revenue Allowance and Reserve Categories	The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the nine months ended September 30, 2023 (in thousands): Balance at Provisions Credit or Adjustments related to prior periods Balance Nine months ended September 30, 2023: Accounts receivable reserves (1) $ 8,179 $ 42,949 $ ( 40,186 ) $ ( 2,629 ) $ 8,313 Revenue reserve accruals (2) $ 10,552 $ 34,848 $ ( 27,528 ) $ 2,297 $ 20,169 (1) Reserves are for chargebacks, discounts and other fees. (2) Accruals are for returns, rebates and other fees.
CpG 1018
Schedule of Revenues from Major Customers	The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant net product revenue): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Largest collaboration partner 0 % 69 % 0 % 46 % Second largest collaboration partner 0 % 22 % 0 % 33 % Third largest collaboration partner 0 % 9 % 0 % 15 %
Summarizes balances and activities in our contract asset account	The following table summarizes balances and activities in our contract asset account (in thousands): Balance at Additions Subtractions Reclassification (1) Balance Nine months ended September 30, 2023: Contract asset, included in other current assets (2) $ 71,965 $ 14,396 $ ( 13,175 ) $ ( 71,307 ) $ 1,879 Contract asset, included in other assets (long term) $ - $ - $ - $ 71,307 $ 71,307 (1) The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 6 for further discussion. (2) The $1.9 million of contract asset is derived from our agreement with the DoD.

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
Net Income Per Share (Tables)	Sep. 30, 2023
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income Per Share	Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Numerator Net income (loss) $ 14,293 $ 63,809 $ ( 6,608 ) $ 225,423 Less: undistributed earnings allocated to participating securities - - - ( 291 ) Net income (loss) attributable to common stockholders, basic 14,293 63,809 ( 6,608 ) 225,132 Add: undistributed earnings allocated to participating securities - - - 291 Less: removal of change in fair value of warrant liability - - - ( 1,801 ) Add: interest expense on convertible notes 1,268 1,262 - 3,780 Net income (loss) attributable to common stockholders, diluted $ 15,561 $ 65,071 $ ( 6,608 ) $ 227,402 Denominator Weighted average common stock outstanding, basic 128,988 127,062 128,515 125,997 Effect of dilutive shares: Stock-based compensation plans 3,665 2,933 - 2,784 Dilutive warrants - - - 109 Convertible Notes (as converted to common stock) 21,543 21,543 - 21,543 Weighted average common stock outstanding, diluted 154,196 151,538 128,515 150,433
Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share	The following were excluded from the calculation of diluted net income (loss) per share as the effect of their inclusion would have been anti-dilutive (in thousands). Three months ended September 30, Nine months ended September 30, 2023 2022 2023 2022 Outstanding securities not included in diluted net income (loss) per share calculation: Stock options and stock awards 5,605 5,214 15,304 7,417 Convertible Notes (as converted to common stock) - - 21,543 - Total 5,605 5,214 36,847 7,417

Equity Plans and Stock-Based _2

Equity Plans and Stock-Based Compensation (Tables)	9 Months Ended
Equity Plans and Stock-Based Compensation (Tables)	Sep. 30, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]
Option Activity under Stock-Based Compensation Plans	The following table summarizes the activity of stock options for the nine months ended September 30, 2023 : Shares Weighted- Weighted- Aggregate Balance as of December 31, 2022 9,339 $ 10.70 4.61 $ 16,291 Options granted 1,968 11.14 Options exercised ( 556 ) 7.80 Options cancelled: Options forfeited (unvested) ( 83 ) 10.96 Options expired (vested) ( 260 ) 21.42 Balance as of September 30, 2023 10,408 $ 10.66 4.38 $ 46,599 Vested and expected to vest as of September 30, 2023 10,211 $ 10.65 4.35 $ 45,949 Exercisable as of September 30, 2023 6,843 $ 10.17 3.64 $ 34,772
Summary of Restricted Stock Units Activity	Number of Shares Weighted-Average Non-vested as of December 31, 2022 3,479 $ 11.00 Granted 2,497 11.16 Vested (1) ( 1,456 ) 10.08 Forfeited ( 218 ) 11.49 Non-vested as of September 30, 2023 4,302 $ 11.38 (1) Inclusive of approximately 582,838 RSUs for the nine months ended September 30, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.
Summary Of Performance Based Restricted Stock Unit	We granted market-based performance restricted stock units (“PSUs”) to certain executives. These PSUs vest upon a specified market condition. The summary of PSU activities for the nine months ended September 30, 2023 is as follows: Number of Shares Weighted-Average Non-vested as of December 31, 2022 193 $ 11.62 Granted 364 18.25 Non-vested as of September 30, 2023 557 $ 15.95
Fair Value-Based Measurements and Weighted-Average Assumptions	The weighted-average assumptions used in the calculations of these fair value measurements are as follows : Stock Options Stock Options Market-Based Performance Stock Units (“PSUs”) Three Months Ended Nine Months Ended Nine Months Ended September 30, September 30, September 30, 2023 2022 2023 2022 2023 2022 Weighted-average fair value per share $ 8.61 $ - $ 7.30 $ 7.97 $ 18.25 $ 11.62 Risk-free interest rate 4.2 % - 4.0 % 2.01 % 4.3 % 1.7 % Expected life (in years) 4.5 - 4.5 4.5 2.9 2.9 Volatility 0.8 - 0.8 0.8 0.9 0.9
Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense recorded in each component of operating expenses in our condensed consolidated statements of operations, and amounts capitalized to our inventories (in thousands ): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Research and development $ 2,339 $ 1,532 $ 6,752 $ 4,271 Selling, general and administrative 7,320 6,019 21,353 17,043 Cost of sales - product 369 323 1,463 626 Inventories 659 739 1,715 2,248 Total $ 10,687 $ 8,613 $ 31,283 $ 24,188

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2023
HEPLISAV-B
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Minimum age approved for vaccine prevention of infection caused	18 years

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of the convertible notes	$ 344,800	$ 344,800
Transfers in or out of Level 3	$ 0	$ 0

Fair Value Hierarchy for Financ

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets
Total assets	$ 698,494	$ 594,809
Money Market Funds
Assets
Total assets	131,837	172,418
U.S. Treasuries
Assets
Total assets	51,589	42,308
U.S. Government Agency Securities
Assets
Total assets	189,312	88,032
Corporate Debt Securities
Assets
Total assets	325,756	292,051
Fair Value, Inputs, Level 1
Assets
Total assets	131,837	172,418
Fair Value, Inputs, Level 1 \| Money Market Funds
Assets
Total assets	131,837	172,418
Fair Value, Inputs, Level 1 \| U.S. Treasuries
Assets
Total assets	0	0
Fair Value, Inputs, Level 1 \| U.S. Government Agency Securities
Assets
Total assets	0	0
Fair Value, Inputs, Level 1 \| Corporate Debt Securities
Assets
Total assets	0	0
Fair Value, Inputs, Level 2
Assets
Total assets	566,657	422,391
Fair Value, Inputs, Level 2 \| Money Market Funds
Assets
Total assets	0	0
Fair Value, Inputs, Level 2 \| U.S. Treasuries
Assets
Total assets	51,589	42,308
Fair Value, Inputs, Level 2 \| U.S. Government Agency Securities
Assets
Total assets	189,312	88,032
Fair Value, Inputs, Level 2 \| Corporate Debt Securities
Assets
Total assets	325,756	292,051
Fair Value, Inputs, Level 3
Assets
Total assets	0	0
Fair Value, Inputs, Level 3 \| Money Market Funds
Assets
Total assets	0	0
Fair Value, Inputs, Level 3 \| U.S. Treasuries
Assets
Total assets	0	0
Fair Value, Inputs, Level 3 \| U.S. Government Agency Securities
Assets
Total assets	0	0
Fair Value, Inputs, Level 3 \| Corporate Debt Securities
Assets
Total assets	$ 0	$ 0

Cash, Cash Equivalents, Restr_3

Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents		$ 154,511	$ 202,004	$ 198,576	$ 436,189
Restricted cash	[1]	266	207	189	219
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows		$ 154,777	$ 202,211	$ 198,765	$ 436,408

[1] (1) Restricted cash is included in "Other assets" in the Condensed Consolidated Balance Sheets.

Cash, Cash Equivalents, Restr_4

Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Summary of Cash, Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	$ 154,511	$ 202,004
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	154,511	202,004
Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	567,417	423,796
Unrealized Gains	6	12
Unrealized Losses	(1,518)	(1,417)
Estimated Fair Value	565,905	422,391
Marketable Securities Available-for-Sale \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	721,928	625,800
Unrealized Gains	6	12
Unrealized Losses	(1,518)	(1,417)
Estimated Fair Value	720,416	624,395
Cash \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	21,922	29,586
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	21,922	29,586
Money Market Funds \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	131,837	172,418
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	131,837	172,418
U.S. Treasuries \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	51,734	42,502
Unrealized Gains	0	0
Unrealized Losses	(145)	(194)
Estimated Fair Value	51,589	42,308
U.S. Government Agency Securities \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	190,323	88,429
Unrealized Gains	0	0
Unrealized Losses	(1,011)	(397)
Estimated Fair Value	189,312	88,032
Corporate Debt Securities \| Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	752
Unrealized Gains	0
Unrealized Losses	0
Estimated Fair Value	752
Corporate Debt Securities \| Marketable Securities Available-for-Sale
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	325,360	292,865
Unrealized Gains	6	12
Unrealized Losses	(362)	(826)
Estimated Fair Value	$ 325,004	$ 292,051

Cash, Cash Equivalents, Restr_5

Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Maturities of Marketable Securities Available-for-Sale (Detail) $ in Thousands	Sep. 30, 2023 USD ($)
Amortized Cost
Mature in one year or less	$ 494,498
Mature after one year through two years	72,919
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Total	567,417
Estimated Fair Value
Mature in one year or less	493,376
Mature after one year through two years	72,529
Total estimated fair value	$ 565,905

Cash, Cash Equivalents, Restr_6

Cash, Cash Equivalents, Restricted Cash and Marketable Securities - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Gross realized losses on investmnents	$ 0	$ 0	$ 0	$ 0

Inventories, Net - Summary of I

Inventories, Net - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 27,469	$ 25,517
Work-in-process	17,515	23,934
Finished goods	4,428	9,995
Total	$ 49,412	$ 59,446

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands, € in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	May 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Nov. 30, 2009 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 EUR (€)	Dec. 31, 2022 USD ($)	May 31, 2021 USD ($)
Loss Contingencies [Line Items]
Lease expiration date						Mar. 31, 2031
Option to extend						The subtenant has no option to extend the sublease term
Sublease income				$ 1,993	$ 2,026	$ 5,584	$ 5,660
Percentage of excess rent paid to landlord				50%		50%		50%
Cash paid for amounts included in the measurement of operating lease liabilities						$ 5,300	$ 5,100
Long-term debt, net of debt discount				$ 3,085		3,085			$ 3,922
Liabilities				54,264		$ 54,264			150,074
Description of Avecia Supply Agreement						On September 7, 2023 (the “Effective Date”), we entered into an agreement (the “Avecia Supply Agreement”) with Nitto Denko Avecia Inc. (“Avecia”) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the “2012 Agreement”). As of September 30, 2023, we have not placed any manufacturing orders under the Avecia Supply Agreement. As of September 30, 2023 and December 31, 2022, we have no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant.
H E P L I S A V B [Member]
Loss Contingencies [Line Items]
Non-cancelable purchase and other commitments				39,800		$ 39,800			$ 43,400
Asset Purchase Agreement
Loss Contingencies [Line Items]
Liabilities				500		500
Symphony Dynamo Holdings LLC
Loss Contingencies [Line Items]
License arrangement contingent consideration percentage			50%
License Arrangement Contingent Payment To Acquire License			$ 50,000
TriSalus
Loss Contingencies [Line Items]
Payment to holdings						2,500
Payment received for Pre-commercialization milestone		$ 1,000
TriSalus \| Asset Purchase Agreement
Loss Contingencies [Line Items]
Payment made for Pre-commercialization milestone	$ 500
Deutsche Bank Securities
Loss Contingencies [Line Items]
Financial Instruments, Owned, at Fair Value \| €								€ 0.2
Deutsche Bank Securities \| Letter of Credit [Member]
Loss Contingencies [Line Items]
Financial Instruments, Owned, at Fair Value \| €								€ 0.2
2.50% Convertible Senior Notes Due 2026
Loss Contingencies [Line Items]
Aggregate principal amount				225,500		225,500				$ 225,500
Long-term debt, net of debt discount				$ 3,100		$ 3,100
California
Loss Contingencies [Line Items]
Lease option to extend						Certain of these leases also include options to renew or extend the lease for two successive five-year terms
California \| Maximum [Member]
Loss Contingencies [Line Items]
Initial lease term				12 years		12 years		12 years
California \| Minimum [Member]
Loss Contingencies [Line Items]
Initial lease term				3 years		3 years		3 years

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Operating Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease expense	$ 1,392	$ 1,377	$ 4,172	$ 4,851

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Current portion of lease liabilities (included in other current liabilities)	$ 4,390	$ 3,631
Long-term portion of lease liabilities	30,680	32,801
Total operating lease liabilities	$ 35,070	$ 36,432

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Maturities of Sublease Income and Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Sublease Income
2023 (remaining)	$ 1,405
2024	5,684
2025	5,854
2026	6,030
2027	6,211
Thereafter	21,500
Total	46,684
Operating Lease Liabilities
2023 (remaining)	1,873
2024	7,579
2025	6,954
2026	6,096
2027	6,026
Thereafter	21,171
Total	49,699
Present value adjustment	(14,629)
Total	$ 35,070	$ 36,432

Commitments and Contingencies_5

Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail)	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Weighted average remaining lease term	6 years 9 months 18 days	7 years 7 months 6 days
Weighted average discount rate	10.10%	10.10%

Collaboration, Development and

Collaboration, Development and Supply Agreements - Additional Information (Detail) - USD ($)		1 Months Ended			3 Months Ended		9 Months Ended
	Apr. 26, 2023	Jul. 31, 2023	Apr. 30, 2023	Sep. 30, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 31, 2023	Apr. 27, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Advance payment from customer					$ (47,401,000)	$ 0	$ (47,401,000)	$ 0
Repayment of Advance from Customer										$ 47,400,000
Prepayment of advance payment			$ 13,500
Account Receivable					519,000		519,000				$ 2,385,000
Allowance for doubtful accounts receivables					12,313,000		12,313,000				0
Revenue recognized					69,514,000	167,735,000	176,688,000	538,191,000
Contract modification amount		$ 33,700,000
Accrued liabilities					43,462,000		43,462,000				30,719,000
CEPI Partners [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Advance payment from customer					175,000,000		175,000,000
Repayment of Advance from Customer					67,300,000		67,300,000
Long-term deferred revenue					0		0				0
Accrued liabilities					47,400,000		47,400,000				107,700,000
Accrual Long Term Balance					60,300,000		60,300,000
Clover
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized					0	87,500,000	0	201,100,000
Clover \| Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract asset balance											$ 71,300,000
Biological E. Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Repayment of Advance from Customer	$ 47,400									47,400,000
Prepayment of advance payment	14,500,000
Additional future payment	5,500,000								$ 12,300,000
Advance payment received	$ 125,000,000								250,000,000
Accounts Receivable Net Current									$ 1,000
Biological E. Limited \| Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized					0	27,600,000	0	146,000,000
U.S. Department of Defense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized					7,200,000	$ 3,900,000	14,500,000	$ 6,600,000
Proceeds from grant				$ 22,000,000
CEPI Member
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts Receivable Net Current										$ 47,400,000
CEPI Member \| Clover
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrual Long Term Balance					$ 60,300,000		$ 60,300,000

Convertible Notes - Additional

Convertible Notes - Additional Information (Detail) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended
	Oct. 01, 2023 Days	May 31, 2021 USD ($)	Sep. 30, 2023 USD ($) Days $ / shares shares
Debt Instrument [Line Items]
Fair value of the convertible notes			$ 344,800
2.50% Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Aggregate principal amount		$ 225,500	225,500
Debt issuance and offering costs		5,700	$ 3,100
Proceeds from issuance of Convertible Notes, net		219,800
Debt instrument, interest rate terms			The Convertible Notes are general, unsecured obligations and accrue interest at a rate of 2.50% per annum payable semiannually in arrears on May 15 and November 15 of each year, beginning on November 15, 2021.
Debt maturity date			May 15, 2026
Initial conversion rate			95.5338
Debt conversion, original debt, principal amount converted			$ 1,000
Debt instrument, conversion price per share \| $ / shares			$ 10.47
Debt instrument, convertible, threshold trading days \| Days	20		20
Debt instrument, convertible, threshold consecutive trading days \| Days	30		30
Debt instrument, convertible, threshold percentage of stock price trigger			130%
Debt Instrument, redemption, description			We may redeem for cash all or any portion of the Convertible Notes (subject to the partial redemption limitation described in the indenture governing the Convertible Notes), at our option, on or after May 20, 2024 and prior to the 31st scheduled trading day immediately preceding the maturity date, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
Debt instrument, redemption earliest date			May 20, 2024
Percentage of principal redeemed			100%
Debt instrument interest rate, effective percentage			3.10%
2.50% Convertible Senior Notes Due 2026 \| Debt Instrument, Conversion, Period One
Debt Instrument [Line Items]
Debt instrument, convertible, threshold trading days \| Days			20
Debt instrument, convertible, threshold consecutive trading days \| Days			30
2.50% Convertible Senior Notes Due 2026 \| Debt Instrument, Conversion, Period One \| Maximum
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger	130%		130%
2.50% Convertible Senior Notes Due 2026 \| Debt Instrument, Conversion, Period Two
Debt Instrument [Line Items]
Debt instrument, convertible, threshold trading days \| Days			5
Debt instrument, convertible, threshold consecutive trading days \| Days			10
2.50% Convertible Senior Notes Due 2026 \| Debt Instrument, Conversion, Period Two \| Maximum
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger			98%
Loan Agreement
Debt Instrument [Line Items]
Repayments of debt		190,200
Capped Calls
Debt Instrument [Line Items]
Net Proceeds to Pay the Costs		$ 27,200	$ 27,200
Number of shares converted \| shares			21,542,871
Initial strike price \| $ / shares			$ 10.47
Initial cap price \| $ / shares			$ 15.8
Reduction to additional paid-in capital, capped calls cost			$ 27,200

Convertible Notes - Summary of

Convertible Notes - Summary of Interest Expenses Related to Convertible Notes (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Debt Disclosure [Abstract]
Stated coupon interest	$ 1,409	$ 1,409	$ 4,227	$ 4,228
Amortization of debt issuance cost	282	273	838	812
Total interest expense	$ 1,691	$ 1,682	$ 5,065	$ 5,040

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation Of Revenue [Line Items]
Total revenues	$ 69,514	$ 167,735	$ 176,688	$ 538,191
UNITED STATES
Disaggregation Of Revenue [Line Items]
Total revenues	69,514	41,385	176,688	96,623
Non-US
Disaggregation Of Revenue [Line Items]
Total revenues	0	126,350	0	441,568
HEPLISAV-B
Disaggregation Of Revenue [Line Items]
Total revenues	62,318	37,508	162,209	90,998
HEPLISAV-B \| UNITED STATES
Disaggregation Of Revenue [Line Items]
Total revenues	62,318	37,508	162,209	90,057
HEPLISAV-B \| Non-US
Disaggregation Of Revenue [Line Items]
Total revenues	0	0	0	941
CpG 1018
Disaggregation Of Revenue [Line Items]
Total revenues	0	126,307	0	440,464
CpG 1018 \| UNITED STATES
Disaggregation Of Revenue [Line Items]
Total revenues	0	0	0	0
CpG 1018 \| Non-US
Disaggregation Of Revenue [Line Items]
Total revenues	0	126,307	0	440,464
Product
Disaggregation Of Revenue [Line Items]
Total revenues	62,318	163,815	162,209	531,462
Product \| UNITED STATES
Disaggregation Of Revenue [Line Items]
Total revenues	62,318	37,508	162,209	90,057
Product \| Non-US
Disaggregation Of Revenue [Line Items]
Total revenues	0	126,307	0	441,405
Other Revenue
Disaggregation Of Revenue [Line Items]
Total revenues	7,196	3,920	14,479	6,729
Other Revenue \| UNITED STATES
Disaggregation Of Revenue [Line Items]
Total revenues	7,196	3,877	14,479	6,566
Other Revenue \| Non-US
Disaggregation Of Revenue [Line Items]
Total revenues	$ 0	$ 43	$ 0	$ 163

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Revenues from Major Customers (Detail) - Product Concentration Risk [Member] - Revenue Benchmark [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Largest Customer \| HEPLISAV-B
Concentration Risk [Line Items]
Percentage of product revenue	27%	23%	25%	20%
Second Largest Customer \| HEPLISAV-B
Concentration Risk [Line Items]
Percentage of product revenue	25%	19%	24%	18%
Third Largest Customer \| HEPLISAV-B
Concentration Risk [Line Items]
Percentage of product revenue	18%	18%	17%	17%
Largest Collaboration Partner \| CpG 1018
Concentration Risk [Line Items]
Percentage of product revenue	0%	69%	0%	46%
Second Largest Collaboration Partner \| CpG 1018
Concentration Risk [Line Items]
Percentage of product revenue	0%	22%	0%	33%
Third largest collaboration partner \| CpG 1018
Concentration Risk [Line Items]
Percentage of product revenue	0%	9%	0%	15%

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Product Revenue Allowance and Reserve Categories (Detail) - HEPLISAV-B $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
SEC Schedule, 12-09, Allowance, Notes Receivable [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 8,179	[1]
Provisions related to current period sales	42,949	[1]
Credit or payments made during the period	(40,186)	[1]
Adjustments related to prior periods	(2,629)	[1]
Balance at End of Period	8,313	[1]
Revenue Reserve Accruals [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	10,552	[2]
Provisions related to current period sales	34,848	[2]
Credit or payments made during the period	(27,528)	[2]
Adjustments related to prior periods	2,297	[2]
Balance at End of Period	$ 20,169	[2]

[1] Reserves are for chargebacks, discounts and other fees. Accruals are for returns, rebates and other fees.

Revenue Recognition - Summary_3

Revenue Recognition - Summary of balances and activities in our contract asset account (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Reclassification	$ 71,307	[1]
Balance at End of Period	71,307
CpG 1018
Balance at Beginning of Period	71,965	[2]
Additions (1)	14,396	[2]
Subtractions (2)	(13,175)	[2]
Reclassification	(71,307)	[1],[2]
Balance at End of Period	$ 1,879	[2]

[1] The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 6 for further discussion. The $1.9 million of contract asset is derived from our agreement with the DoD.

Computation of Basic and Dilute

Computation of Basic and Diluted Net (Loss) Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure Computation Of Basic And Diluted Earnings Per Share [Abstract]
Net Income (Loss)	$ 14,293	$ 63,809	$ (6,608)	$ 225,423
Less: undistributed earnings allocated to participating securities	0	0	0	(291)
Net (loss) income attributable to common stockholders, basic	14,293	63,809	(6,608)	225,132
Add: undistributed earnings allocated to participating securities	0	0	0	291
Less: Removal of change in fair value of warrant liability	0	0	0	(1,801)
Interest Expense, Medium-term Notes	1,268	1,262	0	3,780
Net loss attributable to common stockholders, diluted	$ 15,561	$ 65,071	$ (6,608)	$ 227,402
Weighted average common stock outstanding, basic	128,988	127,062	128,515	125,997
Effect of dilutive shares:
Stock-based compensation plans	3,665	2,933	0	2,784
Effect of dilutive warrants	0	0	0	109
Convertible Notes (as converted to common stock)	21,543	21,543	0	21,543
Weighted average common stock outstanding, diluted	154,196	151,538	128,515	150,433

Outstanding Stock Options and S

Outstanding Stock Options and Stock Awards Excluded from Calculation of Net Loss Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share Disclosure [Line Items]
Outstanding securities not included in diluted net loss per share calculation	5,605	5,214	36,847	7,417
Stock Options and Stock Awards
Earnings Per Share Disclosure [Line Items]
Outstanding securities not included in diluted net loss per share calculation	5,605	5,214	15,304	7,417
Convertible Notes
Earnings Per Share Disclosure [Line Items]
Outstanding securities not included in diluted net loss per share calculation	0	0	21,543	0

Common Stock and Warrants - Add

Common Stock and Warrants - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 06, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Class Of Stock [Line Items]
Common stock, shares outstanding		129,194,842		129,194,842		127,604,000
Change in fair value of warrant liability		$ 0	$ 0	$ 0	$ (1,801)
Warrants
Class Of Stock [Line Items]
Cash Settlement of warrants					$ 8,500
Number of common stock warrants exercised			1,882,600		1,882,600
Warrants \| Other Income, Net
Class Of Stock [Line Items]
Change in fair value of warrant liability					$ 1,800
2020 ATM Agreement
Class Of Stock [Line Items]
Remaining proceeds from common stock, under sales agreement				$ 120,000
Maximum
Class Of Stock [Line Items]
Common stock sales agreement aggregate sales proceeds	$ 120,000
Maximum \| 2020 ATM Agreement
Class Of Stock [Line Items]
Commission on gross sales proceeds of common stock	3%

Equity Plans and Stock-Based _3

Equity Plans and Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	May 31, 2022	Jun. 30, 2021	Jan. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in aggregate number of shares of common stock authorized for issuance						15,000,000
Stock based compensation expense related to restricted stock	$ 0.7	$ 0.2	$ 1.8	$ 0.6
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting period			7 years
Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units awards outstanding	557,000		557,000		193,000
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units awards outstanding	4,302,000		4,302,000		3,479,000
Maximum \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period			10 years
Minimum \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period			7 years
2018 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Newly reserved shares of common stock	9,659,145,000		9,659,145,000				3,250,000	1,500,000
2014 Employee Stock Purchase Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued to employees						32,600,000
Performance Based Vesting Schedule \| Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units awards outstanding	36,000		36,000

Equity Plans and Stock-Based _4

Equity Plans and Stock-Based Compensation - Option Activity under Stock-Based Compensation Plans (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Shares Underlying Outstanding Options
Beginning balance	9,339
Options granted	1,968
Options exercised	(556)
Options cancelled	(83)
Options cancelled	(260)
Ending balance	10,408	9,339
Vested and expected to vest as of September 30, 2023	10,211
Exercisable as of September 30, 2023	6,843
Weighted-Average Exercise Price Per Share
Beginning balance	$ 10.7
Options granted	11.14
Options exercised	7.8
Options cancelled	10.96
Options cancelled	21.42
Ending balance	10.66	$ 10.7
Vested and expected to vest as of June 30, 2023	10.65
Exercisable as of June 30, 2023	$ 10.17
Weighted-Average Remaining Contractual Term (years)
Weighted - Average Remaining Contractual Term (years), balance	4 years 4 months 17 days	4 years 7 months 9 days
Vested and expected to vest as of June 30, 2023	4 years 4 months 6 days
Exercisable as of June 30, 2023	3 years 7 months 20 days
Aggregate Intrinsic Value
Balance as of December 31, 2022	$ 16,291
Balance as of June 30, 2023	46,599	$ 16,291
Vested and expected to vest as of June 30, 2023	45,949
Exercisable as of June 30, 2023	$ 34,772

Equity Plans and Stock-Based _5

Equity Plans and Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs) shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Shares
Non-vested, Beginning Balance \| shares	3,479
Granted \| shares	2,497
Vested \| shares	(1,456)	[1]
Forfeited \| shares	(218)
Non-vested, Ending Balance \| shares	4,302
Weighted-Average Grant-Date Fair Value Per Share
Non-vested, Beginning Balance \| $ / shares	$ 11
Granted \| $ / shares	11.16
Vested \| $ / shares	10.08	[1]
Forfeited \| $ / shares	11.49
Non-vested, Ending Balance \| $ / shares	$ 11.38

[1] (1) Inclusive of approximately 582,838 RSUs for the nine months ended September 30, 2023, which were not converted into shares due to net share settlement in order to cover the required amount of employee withholding taxes. The value of the withheld shares was classified as a reduction to additional paid-in capital.

Equity Plans and Stock-Based _6

Equity Plans and Stock-Based Compensation -Summary Of Performance Based Restricted Stock Unit (Detail) - Performance Based Restricted Stock Units shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Weighted-Average Grant-Date Fair Value Per Share
Non-vested, Beginning Balance \| $ / shares	$ 11.62
Granted \| $ / shares	18.25
Non-vested, Ending Balance \| $ / shares	$ 15.95
Number of Shares
Non-vested, Beginning Balance \| shares	193
Granted \| shares	364
Non-vested, Ending Balance \| shares	557

Equity Plans and Stock-Based _7

Equity Plans and Stock-Based Compensation - Fair Value-Based Measurements and Weighted-Average Assumptions (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value per share	$ 8.61	$ 0	$ 7.3	$ 7.97
Risk-free interest rate	4.20%	0%	4%	2.01%
Expected life (in years)	4 years 6 months		4 years 6 months	4 years 6 months
Volatility	0.80%	0%	0.80%	0.80%
Market Based Performance Stock Unit
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value per share			$ 18.25	$ 11.62
Risk-free interest rate			4.30%	1.70%
Expected life (in years)			2 years 10 months 24 days	2 years 10 months 24 days
Volatility			0.90%	0.90%

Equity Plans and Stock-Based _8

Equity Plans and Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	$ 10,687	$ 8,613	$ 31,283	$ 24,188
Research and Development
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	2,339	1,532	6,752	4,271
Selling, General and Administrative
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	7,320	6,019	21,353	17,043
Cost of Sales - Product
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	369	323	1,463	626
Inventory
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Stock-based compensation expense	$ 659	$ 739	$ 1,715	$ 2,248

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Provision for income taxes	$ (147)	$ 283	$ 1,245	$ 902
Effective Tax Rate	1%		22.90%	0.40%